Fact-checked by Grok 2 weeks ago

Compound heterozygosity

Compound heterozygosity is the presence of two different mutated alleles at a particular locus, one inherited from each . This genetic represents a specific type of heterozygosity where both alleles carry pathogenic variants, but they differ in their molecular alterations, such as distinct point mutations or insertions/deletions within the same . In autosomal recessive disorders, compound heterozygosity often leads to a loss of functional protein from the affected gene, resulting in disease phenotypes comparable to those caused by homozygous mutations. For example, it has been implicated in conditions such as , which increases the risk of life-threatening thrombotic events, and restrictive dermopathy due to mutations in the ZMPSTE24 gene. This mechanism underlies the inheritance pattern in many Mendelian diseases, where carriers of a single mutant are typically , but offspring receiving two different mutants from heterozygous parents manifest the disorder. The identification of compound heterozygosity is critical in clinical genetics, particularly with the advent of and sequencing, as it can explain unresolved cases of recessive traits and inform for hereditary conditions like pediatric cancers. Challenges in detection arise because sequencing data often requires phasing to confirm that the variants are in trans (on different chromosomes) rather than in cis, yet tools and algorithms are improving to infer this configuration from large-scale genomic datasets. Overall, understanding compound heterozygosity enhances diagnostic precision and contributes to broader insights into genetic across populations.

Fundamentals

Definition

Compound heterozygosity refers to the genetic condition in which an individual inherits two different pathogenic variants in the same gene, one from each parent, at a specific locus on a chromosome, resulting in both alleles being altered or non-functional. This genotype is a form of heterozygosity where the two alleles differ from each other and from the wild-type sequence, often leading to a loss of normal gene function in recessive contexts. In genetic terminology, a locus is the fixed position of a gene or DNA sequence on a chromosome. An allele represents one of two or more versions of the DNA sequence at that locus. A variant denotes any alteration in the DNA sequence, which may be pathogenic if it disrupts gene function, whereas a polymorphism is a common variant (typically with a population frequency of at least 1%) that generally does not cause disease. This phenomenon occurs in diploid organisms, such as humans, where each cell contains two copies of each chromosome—one inherited from the mother and one from the father—allowing for two alleles per locus. Inheritance follows Mendelian principles, with each parent contributing one allele to the offspring. The concept of compound heterozygosity emerged in the study of recessive genetic disorders in the mid-20th century, with early descriptions in hemoglobinopathies reported in the 1950s and formal recognition through investigations of metabolic diseases during that era.

Comparison to Homozygosity and Simple Heterozygosity

Compound heterozygosity differs from homozygosity and simple heterozygosity in the nature of the alleles present at a locus and their implications for recessive genetic disorders. In homozygosity, an individual inherits two identical for a given , which may both be normal (homozygous dominant) or both (homozygous recessive), resulting in either no manifestation or full expression of a recessive disorder due to complete loss of . In contrast, simple heterozygosity involves inheriting one normal and one , typically conferring status without phenotypic effects in autosomal recessive conditions, as the normal produces sufficient functional protein. Compound heterozygosity, however, occurs when two different are inherited—one from each parent—leading to a biallelic loss of akin to homozygous recessive states but with potential variations arising from the distinct impacts of each mutation. Phenotypically, both homozygous recessive and compound heterozygous genotypes often produce similar disease outcomes in autosomal recessive disorders, as both result in insufficient functional protein product, manifesting the full disorder. However, compound heterozygosity can lead to variable severity compared to homozygosity, depending on the specific functional deficits caused by the differing mutations; for instance, in cystic fibrosis, compound heterozygotes for certain allele combinations exhibit phenotypes indistinguishable from homozygous cases but with reduced risk for complications like meconium ileus. Simple heterozygosity, by comparison, rarely causes disease, emphasizing its role as a benign carrier state rather than a disease trigger. The following table summarizes key distinctions among these genotypes in the context of autosomal recessive traits:
Genotype TypeAlleles InheritedDisease Risk in Recessive DisordersExample (Hypothetical Gene)
Homozygous NormalTwo identical normal (e.g., AA)NoneFull gene function, no disorder
Simple HeterozygousOne normal, one mutant (e.g., Aa)None (carrier status)Normal phenotype,
Homozygous MutantTwo identical mutants (e.g., aa)High (full disorder expression) with ΔF508/ΔF508
Compound HeterozygousTwo different mutants (e.g., a1a2)High (disorder, potentially variable severity) with ΔF508/G551D

Molecular Basis

Pathogenic Allelic Variants

Pathogenic allelic variants are genetic alterations in a that can disrupt its normal function, often leading to disease when combined in a compound heterozygous state. These variants typically occur in coding or regulatory regions and are classified based on their molecular consequences. Common types include missense , which substitute one for another and may alter or function; nonsense , which introduce premature stop codons resulting in truncated proteins; frameshift , caused by insertions or deletions that shift the and often produce nonfunctional proteins; and splice-site , which disrupt -exon boundaries and lead to aberrant mRNA splicing, such as or intron retention. Variants contributing to compound heterozygosity are further categorized by their functional impact, distinguishing between null alleles, which completely abolish or function (e.g., via nonsense or frameshift mutations leading to mRNA degradation through ), and hypomorphic alleles, which partially impair function (e.g., certain missense or splice-site variants that retain some residual activity). This classification is because the combination of a null and a hypomorphic allele can result in intermediate phenotypes, differing from the severe outcomes of two null alleles. Recent studies have developed kinetic models to describe the functional consequences of such combinations in obligate enzyme dimers, where one in each leads to specific reductions in enzymatic activity depending on the variant types. The pathogenicity of these variants is assessed using standardized criteria, such as the American College of Medical Genetics and Genomics (ACMG) guidelines, which evaluate evidence from population frequency, computational predictions, functional studies, and segregation data to classify variants as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. For instance, a absent in population , predicted to disrupt protein , and supported by functional assays would be deemed pathogenic. These guidelines ensure consistent interpretation across clinical and research settings. Allele-specific effects highlight how distinct variants in the same can produce varying degrees of dysfunction; for example, a missense variant might preserve partial enzymatic activity, while a variant eliminates it entirely, influencing the overall severity in compound heterozygosity. Detection of such variants relies on sequencing technologies, including for targeted validation and next-generation sequencing (NGS) for high-throughput genome-wide identification, enabling the pinpointing of compound heterozygous configurations.

Formation of the Compound Heterozygous Genotype

Compound heterozygosity arises when an individual inherits two different pathogenic variants in the same gene, one from each parent, resulting in a where both are mutant but distinct (e.g., a1/a2). This occurs through standard in autosomal recessive contexts, where each unaffected carrier parent is heterozygous for a unique variant in the gene of interest. During formation (), each parent has a 50% chance of transmitting their mutant to the offspring; upon fertilization, the combination of these distinct mutant from both parents produces the compound heterozygous state. Pathogenic allelic variants, such as missense or loss-of-function mutations, can serve as these distinct contributors when carried separately by the parents. The probability of an offspring inheriting a compound heterozygous follows basic Mendelian principles and can be illustrated using a for parents who are s of different recessive s (e.g., parent 1: A/, parent 2: A/, where A is the wild-type ). Each parent contributes one randomly, yielding four equally likely outcomes: A/A (25%, unaffected non-), A/ (25%, ), A/ (25%, ), and / (25%, compound heterozygous and typically affected). This 1/4 (25%) chance of the compound heterozygous assumes independent assortment and no linkage, applying to recessive traits where the double-mutant state disrupts . In rare instances, a compound heterozygous genotype can form through a , where one pathogenic variant arises spontaneously in the of one parent or early in embryonic development, combining with an inherited variant from the other parent. mutations occur at a low frequency, approximately 10^{-6} per locus per generation, and thus represent an uncommon deviation from the typical biparental inheritance pattern for compound heterozygosity. Epistatic interactions with other genes can modify the phenotypic effects of a compound heterozygous genotype by altering the expression or function of the affected , potentially influencing severity or onset.

Inheritance Patterns

Autosomal Recessive Contexts

In autosomal recessive , pathogenic variants in a located on one of the 22 autosomes lead to manifestation only when both alleles are affected, either through homozygosity for the same variant or compound heterozygosity involving two different pathogenic variants. This pattern requires of one variant from each parent, who remain unaffected as heterozygotes, resulting in a 25% probability of an affected offspring per . Compound heterozygosity represents a of this , where the two distinct variants from each parent together disrupt function sufficiently to produce the recessive . Pedigree analysis of autosomal recessive conditions, including those involving compound heterozygosity, typically reveals a pattern within sibships, where multiple siblings may be affected while parents and prior generations appear unaffected. This occurs because parents (each heterozygous for a different variant in compound cases) transmit the alleles independently, leading to affected children who inherit both, with no male-to-male transmission and equal impact on both sexes. In family trees, the absence of affected individuals in consecutive generations underscores the recessive nature, contrasting with vertical patterns seen in dominant inheritance. Compound heterozygosity is rare in X-linked recessive disorders due to hemizygosity in males, who possess only one X chromosome and thus express any pathogenic variant without a second for compounding. In contrast, autosomal recessive contexts allow for this because both sexes inherit two copies of autosomal genes, enabling the of distinct variants from unrelated parents. From an evolutionary perspective, pathogenic variants underlying autosomal recessive disorders, including those capable of forming compound heterozygous states, are maintained in populations partly through , where carriers exhibit enhanced resistance to certain environmental pressures. For instance, in , heterozygous carriers for the HBB gene variant show protection against severe , contributing to the allele's persistence in malaria-endemic regions despite the recessive disease risk in homozygotes or compound heterozygotes. This balancing selection helps explain the prevalence of such variants, even as compound heterozygosity arises from diverse mutational spectra in outbred populations.

Factors Influencing Prevalence

Consanguinity, characterized by marriages between close relatives such as first cousins, significantly influences the prevalence of compound heterozygosity in autosomal recessive contexts by increasing the likelihood of inheriting two different pathogenic variants from shared ancestral alleles. In populations with high rates, the coefficient elevates the proportion of identical-by-descent homozygotes, but shared ancestry can also facilitate compound heterozygous genotypes when multiple rare variants segregate within the . For instance, calculations show that for an of 0.05 and an inbreeding coefficient of 1/16, the proportion of compound heterozygotes among affected offspring can reach approximately 21%, depending on the relative frequency of non-identical alleles. This dynamic underscores how consanguinity amplifies recessive disease risks, including through compound forms, particularly in regions like the where such practices are common. Founder effects in isolated populations further elevate the prevalence of compound heterozygosity by concentrating specific pathogenic variants at higher frequencies than in the general , increasing the probability that two distinct variants co-occur in trans. In groups such as Ashkenazi Jewish communities, historical bottlenecks have led to elevated carrier rates for multiple alleles in genes associated with recessive disorders, enabling compound heterozygous states when parents carry different variants. For example, in deficiency, compound heterozygosity involving one common mutation and another variant is observed in affected individuals from this , reflecting the genetic legacy of . Similarly, for , the predominant Ashkenazi mutation pairs with other alleles in compound heterozygous cases, highlighting how reduced paradoxically heightens risks for such genotypes in these settings. Migration and population contribute to higher compound heterozygosity risks by promoting that introduces diverse pathogenic variants into previously homogeneous pools, thereby increasing the chance of unrelated individuals carrying different for the same . events, such as those resulting from historical migrations, can generate novel combinations of variants from distinct ancestries, as seen in hypotheses explaining compound heterozygous mutations in genes like OCA2 among admixed groups. This process enhances overall heterozygosity and elevates the potential for trans configurations of rare variants, particularly in urbanizing or populations where inter-ethnic mixing occurs. In admixed cohorts, local ancestry inference reveals how such shapes variant co-occurrence, amplifying recessive risks beyond baseline frequencies. Databases like the Genome Aggregation Database (gnomAD) provide critical data to estimate the of compound heterozygosity by quantifying rare variant co-occurrences across diverse populations. gnomAD's phasing estimates and co-occurrence counts per allow researchers to predict compound heterozygous risks, revealing that at frequencies below 1%, thousands of individuals carry potential pairs in disease-associated genes. For instance, analysis of gnomAD exomes identifies predicted compound heterozygous loss-of-function variants in over 28 genes, informing population-level risks and highlighting disparities in variant distribution. These resources enable precise modeling of compound heterozygosity probabilities, essential for understanding epidemiological patterns without relying on small-scale studies.

Clinical Significance

Associated Genetic Disorders

Compound heterozygosity plays a pivotal role in the etiology of various autosomal recessive genetic disorders, particularly in outbred populations where homozygous mutations are less common. Common categories include metabolic disorders such as enzyme deficiencies (e.g., medium-chain [MCAD] deficiency caused by biallelic variants in ACADM, leading to impaired oxidation and hypoketotic ). Hemoglobinopathies, such as variants like HbSC or HbSD, arise from compound heterozygous hemoglobin beta-chain mutations, resulting in and vaso-occlusive crises. Neuromuscular conditions, including early-onset due to PRKN gene structural variants and from deletions combined with point mutations, also frequently involve this genotype, manifesting as degeneration or . The phenotype-genotype correlation in compound heterozygosity is characterized by variability in disease severity, often determined by the functional impact of the combined s, with the milder typically dictating the overall expression. For instance, in metabolic deficiencies, one null variant paired with a hypomorphic variant may produce a partial activity, leading to milder forms compared to two severe loss-of-function alleles. In hemoglobinopathies, combinations like HbS with HbC result in intermediate and reduced transfusion needs relative to homozygous HbSS. Similarly, neuromuscular disorders exhibit earlier onset or more severe progression when both variants disrupt protein function synergistically, as seen in PRKN-related . This variability underscores the need for variant-specific assessment to predict clinical outcomes. Globally, compound heterozygous configurations account for a substantial proportion of autosomal recessive disorders, especially in non-consanguineous populations where diverse mutations predominate. Approximately 6.5% of individuals in large cohorts like the carry potentially damaging compound heterozygous variants across protein-coding genes, with about 1% involving OMIM-linked recessive traits. In hemoglobinopathies, around 1.1% of couples worldwide are at risk of affected offspring, many through compound heterozygosity. For specific conditions like MCAD deficiency, prevalence reaches 1 in 100,000 births in certain regions, predominantly as compound heterozygotes. Recognizing compound heterozygosity has key therapeutic implications, as it informs personalized treatment strategies by revealing residual protein function or variant interactions. In metabolic disorders, identifying hypomorphic variants can guide enzyme replacement therapy (ERT) dosing, potentially improving outcomes in conditions like lysosomal storage diseases where partial activity modulates response. For hemoglobinopathies, genotype awareness supports targeted interventions like hydroxyurea, which may be more effective in milder compound forms. Overall, phased variant analysis enhances prognostic accuracy and optimizes therapies, reducing risks like metabolic decompensation in enzyme deficiencies.

Diagnosis and Genetic Counseling

Diagnosis of compound heterozygosity primarily relies on advanced genetic sequencing techniques, such as whole exome sequencing (WES) and (WGS), which enable the identification of two different pathogenic variants in the same gene from each parent. These methods involve variant calling algorithms to detect heterozygous variants and assess their phase, determining if they occur in (on different chromosomes) to confirm compound heterozygosity rather than heterozygosity. typically requires segregation studies, where parental DNA is analyzed via targeted to verify that each parent carries one of the variants, thus establishing the compound heterozygous in the affected . The American College of and Genomics (ACMG) guidelines recommend integrating such segregation data with population frequency, predictions, and functional evidence to classify variants as pathogenic. Prenatal screening for compound heterozygosity in at-risk families often employs non-invasive prenatal testing (NIPT) or invasive methods like combined with trio-WES to detect fetal variants early in gestation, particularly for known recessive disorders. Newborn screening programs, increasingly incorporating genomic approaches such as rapid WGS, play a crucial role in early detection by identifying biallelic variants in genes associated with treatable conditions, allowing intervention within the first days of life. For instance, population-based genomic has demonstrated feasibility in detecting variants, including compound heterozygous ones, for over 400 genes linked to pediatric disorders, with yields around 1-2% in general populations. In contrast, diagnostic yields reach 10-20% when applying genomic sequencing to undiagnosed newborns with clinical suspicion of genetic disease. These tools are most effective in populations with high frequencies for specific disorders, emphasizing the need for targeted in diverse ethnic groups. Genetic counseling for individuals with compound heterozygosity focuses on elucidating recurrence risks, which for autosomal recessive conditions are 25% per pregnancy if both parents are carriers, and advising on options like in vitro fertilization (IVF) coupled with preimplantation genetic testing (PGT) to select unaffected embryos. Counselors explain carrier status implications for relatives, recommending cascade screening to identify at-risk family members and prevent transmission. Ethical considerations include ensuring informed consent, maintaining confidentiality of genetic information, and addressing psychosocial impacts such as stigma or family dynamics, while upholding non-directive counseling to respect reproductive autonomy. Preconception carrier screening is advised to inform these decisions, with PGT-M (for monogenic disorders) offering up to 95% accuracy in avoiding affected offspring. A major challenge in diagnosing compound heterozygosity is interpreting variants of uncertain significance (VUS), which constitute 20-40% of findings in WES/WGS and complicate when one is pathogenic and the other a VUS, potentially leading to misdiagnosis or delayed care. In compound contexts, VUS require additional like functional assays or patterns to reclassify them, but limitations in data for rare alleles often result in prolonged uncertainty. ACMG/AMP frameworks guide this process, prioritizing multidisciplinary review, yet ethical dilemmas arise in counseling families on inconclusive results, balancing hope for clarity with avoidance of overinterpretation. Ongoing efforts, including large-scale databases like ClinVar, aim to reduce VUS rates through shared , improving diagnostic confidence.

Notable Examples

Cystic Fibrosis Cases

Compound heterozygosity in the CFTR gene is a common cause of (CF), with the most prevalent mutation being ΔF508 (p.Phe508del), a class II variant that leads to protein misfolding and retention in the , resulting in minimal functional CFTR at the cell surface. When paired with G542X (p.Gly542X), a class I that introduces a premature and abolishes protein production, the resulting typically yields severe CF phenotypes due to near-complete loss of CFTR function. In contrast, ΔF508 combined with R117H (p.Arg117His), a class IV mutation impairing channel conductance but allowing some residual function, often produces milder effects, as the R117H variant permits partial . These combinations highlight how the interplay of alleles determines severity. Phenotypic variation in these compound heterozygous cases arises from the dominant functional defect of the milder . For ΔF508/G542X patients, sweat levels are markedly elevated, averaging 103 mmol/L, reflecting profound CFTR dysfunction, alongside pancreatic insufficiency in over 95% of cases and reduced with mean forced expiratory volume in 1 second (FEV1) around 87% predicted in early adulthood. Survival rates are lower compared to milder genotypes, with increased risk of early due to persistent and . Conversely, ΔF508/R117H individuals exhibit sweat concentrations of approximately 80 mmol/L, pancreatic sufficiency in 87% of cases, and comparable to ΔF508 homozygotes, though with variable progression influenced by the intronic poly-T tract (e.g., 5T allele worsens outcomes). These differences underscore the allele-specific contributions to organ involvement, with severe combinations accelerating pulmonary decline while milder ones delay onset. Historical case studies from the illustrate diagnostic challenges and 's role. A 1993 study described three adolescents with milder symptoms, including borderline sweat chlorides (60-80 mmol/L) and pancreatic sufficiency, diagnosed as ΔF508/R117H via sequencing after atypical presentations like or recurrent , highlighting delayed recognition before routine in the late . By the 2000s, expanded integrated sweat tests with CFTR panels, enabling earlier identification of such genotypes in asymptomatic carriers' offspring. Treatment with CFTR modulators is genotype-tailored, offering functional rescue for specific compounds. , a potentiator enhancing gating, is approved for R117H-containing genotypes like ΔF508/R117H, reducing sweat by 20-50 mmol/L and improving FEV1 by 5-10% in clinical trials, particularly when combined with correctors for the ΔF508 . For ΔF508/G542X, therapies like show limited efficacy, but the triple combination partially corrects ΔF508 trafficking, yielding FEV1 gains of approximately 11-14% in patients with one ΔF508 and a minimal like G542X, based on phase 3 trials as of 2019, with sustained benefits observed in real-world data through 2023. These therapies emphasize personalized approaches based on compound heterozygosity. As of 2025, ongoing research includes gene editing therapies targeting like G542X.

Phenylketonuria Cases

Phenylketonuria (PKU), an autosomal recessive disorder caused by pathogenic variants in the PAH gene on 12q23.2, frequently manifests through compound heterozygosity, where individuals inherit two distinct loss-of-function alleles. A prevalent example in populations involves the missense variant c.1222C>T (p.Arg408Trp; R408W) in exon 12, resulting from a CGG-to-TGG transition that substitutes with at residue 408, and the intronic splice site variant c.1315+1G>A (IVS12+1G>A), which disrupts normal mRNA splicing. These variants lead to deficient (PAH) enzyme, essential for converting to in the presence of (BH4) and molecular oxygen. Compound heterozygous patients with this combination exhibit classic PKU phenotypes, characterized by negligible residual PAH activity (typically 0-1%), as both alleles are null or severely disruptive. Biochemically, compound heterozygosity for such PAH variants impairs the hepatic catabolism of , causing its accumulation in blood and tissues (hyperphenylalaninemia, often >1200 μmol/L untreated). Excess and its metabolites, including phenylketones, exert neurotoxic effects by disrupting myelination, synthesis, and transport across the blood-brain barrier, leading to irreversible , seizures, and behavioral issues if not managed early. In compound heterozygous cases like R408W/IVS12+1G>A, the combined allelic effects yield 0-5% residual activity, correlating with severe metabolic derangement and levels necessitating strict intervention to prevent neurological damage. The disorder was first identified in 1934 by Norwegian biochemist Asbjørn Følling, who detected phenylpyruvic acid in the urine of two siblings with intellectual disability, linking it to an inborn error of metabolism. Widespread newborn screening programs, pioneered by Robert Guthrie in the early 1960s using bacterial inhibition assays on blood spots, identified thousands of PKU cases globally, many later confirmed as compound heterozygous through molecular genotyping starting in the late 1980s. These efforts revealed that over 70% of PKU patients are compound heterozygotes, with variant combinations like R408W/IVS12+1G>A common in Slavic and Northern European cohorts. Management of compound heterozygous PKU centers on lifelong dietary restriction of via low-protein formulas and supplements to maintain blood levels at 120-360 μmol/L, preventing neurocognitive deficits. Sapropterin dihydrochloride (BH4 analog) enhances residual PAH activity in responsive genotypes (20-50% of cases), allowing relaxed dietary restrictions, but severe compound heterozygous variants like R408W/IVS12+1G>A typically show poor (<10% Phe reduction) due to minimal stability. Genotype-phenotype correlations guide testing for BH4 loading, prioritizing milder alleles for potential non-dietary adjuncts. As of 2025, emerging substitution therapies and gene therapies are in clinical trials for severe genotypes, offering potential alternatives to lifelong diet.

References

  1. [1]
    Definition of compound heterozygosity - NCI Dictionary of Genetics ...
    Listen to pronunciation. (KOM-pownd HEH-teh-roh-zy-GAH-sih-tee) The presence of two different mutated alleles at a particular gene locus.
  2. [2]
    Compound Heterozygous Variants in Pediatric Cancers - NIH
    May 19, 2020 · A compound heterozygous (CH) variant is a type of germline variant that occurs when each parent donates one alternate allele and these alleles ...
  3. [3]
    Genetics: MedlinePlus Medical Encyclopedia
    Mar 31, 2024 · If a child receives a variant recessive disease gene from both parents, the child will show the disease and will be homozygous (or compound ...
  4. [4]
    Compound heterozygosity for one novel and one recurrent mutation ...
    Homozygous or compound heterozygous protein S (PS) deficiency is a very rare disorder in the anticoagulant system, that can lead to life-threatening ...
  5. [5]
  6. [6]
    Exome-wide evidence of compound heterozygous effects across ...
    Permutation testing to establish the impact of genetic phase on disease risk. It is commonly accepted that compound heterozygosity drives recessive disease risk ...
  7. [7]
    Inferring compound heterozygosity from large-scale exome ... - Nature
    Dec 6, 2023 · A rare variant analysis framework using public genotype summary counts to prioritize disease-predisposition genes ... compound heterozygosity.
  8. [8]
    Inferring compound heterozygosity from large-scale exome ...
    Mar 23, 2023 · Compound heterozygous variants present a challenge in genetic diagnosis because two variants observed within a gene in an individual can occur ...
  9. [9]
    Definition of heterozygous genotype - NCI Dictionary of Genetics ...
    A heterozygous genotype may include one normal allele and one mutated allele or two different mutated alleles (compound heterozygote).
  10. [10]
    Talking Glossary of Genetic Terms | NHGRI
    An allele is one of two or more versions of DNA sequence (a single base or a segment of bases) at a given genomic location. An individual inherits two alleles, ...
  11. [11]
    GeneReviews Glossary - NCBI
    See PCR. polymorphism. A natural variation in a gene, DNA sequence, protein ... Related terms: allele; benign variant; variant of uncertain significance.
  12. [12]
    A glossary of relevant genetic terms - PMC - NIH
    A gene locus is defined as polymorphic if a rare allele has a frequency of 0.01 (1%) or more.
  13. [13]
    Does Elevated Hemoglobin F Modulate the Phenotype in Hb SD ...
    Jan 21, 2010 · Cases of compound heterozygosity for Hbs S and D-Los Angeles have been reported from the early 1950s and all the patients (albeit with low ...
  14. [14]
  15. [15]
  16. [16]
    Correlation between Genotype and Phenotype in Patients with ...
    Oct 28, 1993 · Compound heterozygotes for G551D and δF508 were indistinguishable from matched δF508 homozygotes except for a decreased risk of meconium ileus.<|control11|><|separator|>
  17. [17]
    Jumping on the Train of Personalized Medicine: A Primer for ... - NIH
    Punnett squares which are used to predict the chance of genetic disease ... This phenomenon is called compound heterozygosity. Compound heterozygotes ...
  18. [18]
    Compound Heterozygous Variants in Pediatric Cancers - Frontiers
    Overview of Pediatric Cancer Types and Genes Studied ... compound heterozygosity, variant pathogenicity assessment, genetic analysis of complex diseases.
  19. [19]
    De novo mutations in autosomal recessive congenital malformations
    Jun 9, 2016 · Compound heterozygous loss-of-function variants in EVC2 were identified in the first fetus. Variants in this gene have been shown to cause Ellis ...
  20. [20]
    A Model of Compound Heterozygous, Loss-of-Function Alleles Is ...
    Under the GBR model, large trait values are usually due to compound heterozygote genotypes (e.g., Ab/aB, where A and B represent different sites in the same ...
  21. [21]
    Genetics, Autosomal Recessive - StatPearls - NCBI Bookshelf
    Using the multiplication rule of probability, there is a 50% chance that the father passes on his disease allele and a 50% chance that the mother passes on her ...
  22. [22]
    Autosomal recessive inheritance — Knowledge Hub
    When someone has two different causal variants, this is termed compound heterozygous. Where one parent is a carrier. As highlighted above, if both parents are ...
  23. [23]
    Autosomal Recessive Inheritance - an overview | ScienceDirect Topics
    Visually, the autosomal recessive pedigree typically shows a horizontal pattern where multiple affected individuals can be observed within the same sibship, and ...
  24. [24]
    Genetics, X-Linked Inheritance - StatPearls - NCBI Bookshelf
    X linked Recessive Inheritance​​ Healthy heterozygous carrier females pass the disorder to affected sons. So from affected males, it can be transmitted to male ...
  25. [25]
    Heterozygote Advantage - an overview | ScienceDirect Topics
    Heterozygote advantage is defined as a mechanism that maintains two alleles in a population, exemplified by the sickle hemoglobin polymorphism and its ...
  26. [26]
    Autosomal recessive disease in children of consanguineous parents
    This short communication deals with the questions of how to calculate the expected proportion of compound heterozygous patients among affected offspring of ...
  27. [27]
    Factor XI Deficiency in Ashkenazi Jews in Israel
    Jul 18, 1991 · Three Ashkenazi Jewish patients were compound heterozygotes, each of whom carried one unidentified defective gene. In two of these three ...
  28. [28]
    The Ashkenazic Jewish Bloom Syndrome Mutation blm Ash Is ...
    In one family, blmAsh was compound heterozygous in the affected person, being transmitted by the Ashkenazic parent. ... founder effect occurred in the Ashkenazic ...
  29. [29]
    Ancestral origins of TYR and OCA2 gene mutations in ...
    Nov 18, 2024 · We refer to this phenomenon as the admixture-derived compound heterozygote hypothesis [24, 25]. In support of this idea, the G47D mutation ...
  30. [30]
    On the heterozygosity of an admixed population - PubMed - NIH
    We show that the heterozygosity of the admixed population is at least as great as that of the least heterozygous source population, and that it potentially ...
  31. [31]
    Variant Co-occurrence Counts by Gene in gnomAD
    Mar 14, 2023 · This presents the opportunity to determine whether individuals in gnomAD carry compound heterozygous (in trans) rare damaging variants in a gene ...
  32. [32]
    MCAD deficiency caused by compound heterozygous pathogenic ...
    Jan 17, 2022 · Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency is an autosomal recessive disease caused by biallelic pathogenic ACADM variants.
  33. [33]
    Compound heterozygosity for hemoglobin S and D - NIH
    Jun 23, 2016 · Compound heterozygotes in which Hb S is inherited in combination with another hemoglobin variant; the most common in Brazil are Hb SC and Hb SD.
  34. [34]
    Compound Heterozygous Structural Variants in Cases with ...
    Aug 30, 2025 · Variants in the PRKN gene are the most common cause of autosomal recessive PD, accounting for between 2.6% and 14.9% of early-onset Parkinson's ...
  35. [35]
    Spinal Muscular Atrophy—Two Case Reports of Compound ...
    Aug 29, 2019 · 5% of patients present as compound heterozygotes in which they have only one deletion of SMN1 and a subtle mutation of the other chromosome.
  36. [36]
    Global epidemiology of haemoglobin disorders and derived service ...
    Around 1.1% of couples worldwide are at risk for having children with a haemoglobin disorder and 2.7 per 1000 conceptions are affected. Prevention is making ...
  37. [37]
    Clinical characteristics and effects of enzyme replacement therapy ...
    Apr 15, 2022 · We report clinical characteristics and outcomes of ERT in 9 patients with MPS IVA (6 males and 3 females) from 7 unrelated families.
  38. [38]
    Gene Therapy for HbSC Disease and other Compound ...
    Aug 20, 2025 · HbSC disease, caused by compound heterozygosity for HbS and HbC genes, is the second most common genotype of sickle cell disease. Gene therapy ...
  39. [39]
    [PDF] Inferring compound heterozygosity from large-scale exome ... - bioRxiv
    Aug 21, 2023 · “knock-out” due to compound heterozygosity. To aid the medical genetics community in interpreting the clinical significance of rare co-.
  40. [40]
    Whole-exome sequencing in undiagnosed genetic diseases
    Whole-exome sequencing (WES) has emerged as a successful diagnostic tool in the study of genetic disease and has proven to be particularly effective in ...
  41. [41]
    Whole exome sequencing identifies compound heterozygous ... - NIH
    Whole exome sequencing identifies compound heterozygous variants of CR2 gene in monozygotic twin patients with common variable immunodeficiency - PMC.
  42. [42]
    Familial co-segregation and the emerging role of long-read ... - NIH
    Aug 10, 2023 · Familial co-segregation analysis reveals chromosomal origin of pathogenic variants in a compound heterozygote. To identify if variants ...
  43. [43]
    ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 ...
    We provide a points-based system for evaluating phenotype and co-segregation as evidence types to support or refute a locus and show how that can be integrated ...
  44. [44]
    Prenatal detection of novel compound heterozygous variants ... - NIH
    Nov 1, 2024 · Our study identified novel variants to expand the mutation spectrum of CHD and provided reliable evidence for the recurrent risk and reproductive care options.
  45. [45]
    A Genomic Sequencing Approach to Newborn Mass Screening
    Oct 17, 2025 · This cohort study examines the feasibility, potential utility, and clinical implications of next-generation sequencing–based newborn ...
  46. [46]
    Population-based, first-tier genomic newborn screening in ... - Nature
    Jan 28, 2025 · A workflow was developed to screen newborns for 165 treatable pediatric disorders by deep sequencing of regions of interest in 405 genes.Missing: prenatal | Show results with:prenatal
  47. [47]
    Genetic Counseling and Assisted Reproductive Technologies - PMC
    PGT-A is used for sex selection when there is a risk for sex-linked conditions, sex-specific issues without a clear Mendelian pattern of inheritance (i.e., ...Missing: compound | Show results with:compound
  48. [48]
    Couple screening for recessively inherited disorders - Sage Journals
    Nov 17, 2022 · Couple screening aims to identify couples with an increased risk of having a child affected with an autosomal recessive or X-linked disorder.
  49. [49]
    Social, Legal, and Ethical Implications of Genetic Testing - NCBI - NIH
    Issues of justice, fairness, and equity crop up in several actions, practices, and policies relating to genetic testing. It is now commonplace to distinguish ...
  50. [50]
    Preconception carrier screening and preimplantation genetic testing ...
    Aug 21, 2024 · The use of CS and PGT is currently considered the most effective intervention for avoiding both an affected pregnancy whilst using autologous gametes.
  51. [51]
    The challenge of genetic variants of uncertain clinical significance
    Addressing the VUS Challenge. Efforts to launch genomic medicine have included significant investments to improve variant interpretation and reduce VUS.
  52. [52]
    Variants of uncertain significance in newborn screening disorders
    All of the 15 private VUS were compound heterozygous with a pathogenic or likely pathogenic PAH variant. In four of these cases, the results of plasma amino ...
  53. [53]
    From uncertain to certain—how to proceed with variants of uncertain ...
    Aug 16, 2024 · As per the ACMG guidelines, VUS are carrying pathogenicity probability between 0.05 and 0.949 [1]. This is the widest probability range among ...
  54. [54]
    4 Issues in Genetic Counseling - The National Academies Press
    Among these critical issues are nondirectiveness; informed consent; confidentiality; multiplex testing; recognizing social and cultural differences;
  55. [55]
    Consensus on the use and interpretation of cystic fibrosis mutation ...
    In compound heterozygosity with a CF-causing mutation, or in homozygosity, R117H-T5 generally results in pancreatic sufficient CF, while R117H-T7 may result in ...
  56. [56]
    Cystic fibrosis mutations for p.F508del compound heterozygotes ...
    We analyzed whether genotype–phenotype correlations exist between CFTR mutations and four clinical phenotypes – sweat chloride levels, pancreatic suffi-ciency, ...Missing: ΔF508 | Show results with:ΔF508
  57. [57]
    In Vivo and In Vitro Ivacaftor Response in Cystic Fibrosis Patients ...
    Ivacaftor is approved for R117H and nine CFTR class III mutations, which encompasses 6% of CF patients in the US. Lumacaftor is approved only for F508del ...
  58. [58]
    CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era ...
    This review aims to provide a summary of recent developments in CFTR-directed therapeutics. Barriers and future directions are also discussed.
  59. [59]
    The analysis of using a panel of the most common variants in the ...
    This variant is caused by a CGG-to-TGG transition in exon 12, resulting in an amino acid substitution (Arg-to-Trp) at residue 408 (R408W) of PAH gene and is a ...
  60. [60]
    The molecular basis of phenylketonuria in Koreans - Nature
    Nov 1, 2004 · For example, in Europe, there are several prevalent founder alleles, including R408W, IVS12+1G>A, IVS10−11G>A, and Y414C, that represent the ...Introduction · Subjects And Methods · Results And Discussion
  61. [61]
    Genetics of Phenylketonuria: Then and Now - Wiley Online Library
    Feb 26, 2016 · More than 950 phenylalanine hydroxylase (PAH) gene variants have been identified in people with phenylketonuria (PKU). These vary in their ...
  62. [62]
    Phenylalanine Hydroxylase Deficiency - GeneReviews - NCBI - NIH
    Mar 13, 2025 · PAH deficiency is characterized by irreversible neurocognitive impairment (intellectual disability), neurobehavioral/psychological issues, neurologic ...Missing: damage | Show results with:damage
  63. [63]
    Entry - #261600 - PHENYLKETONURIA; PKU - OMIM - (OMIM.ORG)
    If undiagnosed and untreated, phenylketonuria can result in impaired postnatal cognitive development resulting from a neurotoxic effect of hyperphenylalaninemia ...
  64. [64]
    The Early History of PKU - PMC - NIH
    Jul 29, 2020 · The story of phenylketonuria (PKU) started in 1934 with Asbjørn Følling's examination of two mentally retarded siblings from a Norwegian family.
  65. [65]
    The Political History of PKU: Reflections on 50 Years of Newborn ...
    Just over 50 years ago, Dr Robert Guthrie developed a simple screening test for phenylketonuria (PKU) that became the prototype for universal newborn screening ...
  66. [66]
    Genotypes of 2579 patients with phenylketonuria reveal a high rate ...
    Jan 22, 2019 · Two typical “northern European” PAH gene mutations include the severe splice site variant IVS12+1G>A and mild p.Tyr414Cys missense variant.Missing: examples | Show results with:examples
  67. [67]
    Phenylketonuria - StatPearls - NCBI Bookshelf
    Phenylketonuria (PKU) is an inborn error of metabolism (IEM) most often caused by missense mutations in the gene encoding phenylalanine hydroxylase (PAH).Missing: neurological | Show results with:neurological
  68. [68]
    Influence of PAH Genotype on Sapropterin Response in PKU - NIH
    PAH was sequenced in all patients. Mutations were correlated with sapropterin response. Dietary Phe intake was increased over a 6-week period in responsive ...Missing: interventions | Show results with:interventions
  69. [69]
    Genomic profiling, implications for genotype-based treatment of 131 ...
    Jun 5, 2025 · This study comprised genomic profiling and phenotypic characterization of 131 Serbian PKU patients along with implications for BH4 therapy.